Fate Therapeutics CFO Edward Dulac receives $5.7M in 2020
Fate Therapeutics reports 2020 executive compensation
By ExecPay News
Published: April 21, 2021
Fate Therapeutics reported fiscal year 2020 executive compensation information on April 21, 2021.
In 2020, five executives at Fate Therapeutics received on average a compensation package of $3.7M, a 22% decrease compared to previous year.
Average pay of disclosed executives at Fate Therapeutics
Edward J. Dulac III, Chief Financial Officer, received $5.7M in total. 67% of Dulac's compensation, or $3.8M, was in option awards. Dulac also received $138K in bonus, $76K in non-equity incentive plan, $143K in salary, $1.4M in stock awards, as well as $120K in other compensation.
J. Scott Wolchko, Chief Executive Officer, received a compensation package of $5.6M, which decreased by 48% compared to previous year. 58% of the compensation package, or $3.2M, was in option awards.
Bahram Valamehr, Chief Research and Development Officer, earned $2.5M in 2020, a 13% decrease compared to previous year.
Cindy R. Tahl, General Counsel, received $2.5M in 2020, which decreases by 13% compared to 2019.
Daniel D. Shoemaker, Chief Scientific Officer, earned $2.5M in 2020, a 13% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 21, 2021.